Stocktoria

ENDONOVO THERAPEUTICS, INC. ENDV

OTC · stock · Electromedical & Electrotherapeutic Apparatus · website · IPO 2012-03-09

ENDONOVO THERAPEUTICS, INC. financials (annual, from 10-K)

Revenue
2013201420152016201720182019202020212022
Net income
2013201420152016201720182019202020212022
Free cash flow
2013201420152016201720182019202020212022

Bars are annual figures from 2013 to 2022; red bars are negative (a loss or cash outflow).

MetricFY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014FY2013
Revenue$135,355$73,105$165,796$310,164$83,263$4,265$24,192$22,896
Gross profit$125,365$58,120$100,427$216,779$70,333$2,103$8,707$8,903
R&D expense$0$3,283$153,126$274,265$115,159$0
Operating income-$3.3M-$2.2M-$2.9M-$3.8M-$4.2M-$4.6M-$5.4M-$2.6M-$2.2M-$2.4M
Interest expense$941,566$2.1M
Income tax$0$0$532
Net income-$18.5M-$3.1M-$395,584-$17.3M-$6.4M-$10.8M-$5.3M-$6.8M-$959,494-$2.9M
Operating cash flow-$678,838-$986,584-$741,590-$2.5M-$2.9M-$3.0M-$2.5M-$1.0M-$909,296-$257,416
Free cash flow-$2.5M-$2.9M-$1.0M-$909,296
Cash & equivalents$98$85,936$13,420$18,893$379,151$90,173$55,533$41,473$988$3,255
Total assets$1.3M$2.0M$2.6M$3.3M$4.2M$4.6M$318,679$409,363$45,589$73,593
Total liabilities$33.5M$17.8M$17.0M$23.8M$15.6M$14.2M$8.9M$9.7M$4.7M$4.2M
Shareholders' equity-$32.2M-$15.8M-$14.4M-$20.5M-$11.4M-$9.6M-$8.6M-$9.3M-$4.7M-$4.1M

Growth · year-over-year · Revenue CAGR 28.9%

MetricFY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014FY2013
Revenue growth+85.2%-55.9%-46.5%+272.5%-82.4%+5.7%-49.7%

Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.

Source: SEC EDGAR filings · CIK 0001528172 · US · as of 2022-12-31. facts plus Stocktoria's own computed scores — not investment advice.